Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05127590
Title RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ribon Therapeutics, Inc.

lung squamous cell carcinoma


Pembrolizumab + RBN-2397

Age Groups: adult | senior
Covered Countries USA | ESP

No variant requirements are available.